7 unknown, 5 recruiting, 4 completed, 2 not yet recruiting. 20 Phase 3, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 20 | Unknown 7, Recruiting 5, Completed 4, Not yet recruiting 2, Terminated 1, Withdrawn 1 |
| Phase 2 | 6 | Unknown 3, Completed 2, Not yet recruiting 1 |
Follow mFOLFOX6: new trials by email Literature Review of mFOLFOX6 trials Research Report on mFOLFOX6
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer (LiGeR-CRC1) Petosemtamab, Cetuximab, FOLFIRI - Left-sided Colorectal Cancer | Phase 3 | Recruiting | Genmab | 960 | 2026-08-11 | 2026-11-03 |
| SCRT + Chemo Targeted Immuno-neoadjuvant Therapy for High-risk pMMR/MSS RC Short-Course Radiotherapy, PD-1 monoclonal antibody, mFOLFOX6 regimen - Rectal Adenocarcinoma, High-Risk Cancer | Phase 3 | Recruiting | Sixth Affiliated Hospital, Sun Yat-sen University | 204 | 2026-05-20 | 2026-07-01 |
| A Clinical Study to Evaluate the Efficacy and Safety of Envafolimab Combined With Cetuxima-βand mFOLFOX6 in Patients With MSS, RAS/BRAF Wild-Type Metastatic Colorectal Cancer (mCRC) Cetuxima-β, Envafolimab, mFOLFOX6 - Metastatic Colorectal Cancer (CRC) | Phase 2 / Phase 3 | Not yet recruiting | Sun Yat-sen University | 590 | 2025-06-01 | 2025-05-06 |
| mFOLFOX6 + Bevacizumab + PD-1 Monoclonal Antibody Vs. mFOLFOX6 in Locally Advanced pMMR/MSS CRC mFOLFOX6 + Bevacizumab + PD-1 monoclonal antibody, mFOLFOX6 - Colorectal Cancer (CRC), pMMR/MSS Adenocarcinoma of the Colon or Rectum | Phase 3 | Recruiting | Jun Huang | 166 | 2025-01-18 | 2025-12-24 |
| Adjuvant mFOLFOXIRI vs. mFOLFOX6 in MRD Positive Stage II-III Colorectal Cancer (AFFORD) mFOLFOXIRI, mFOLFOX6 - Colorectal Cancer | Phase 3 | Not yet recruiting | Yanhong Deng | 340 | 2022-10-09 | 2022-10-07 |
| A Study Assessing the Interchangeability Between TRS003 and Bevacizumab® For CRC TRS003, China-approved Bevacizumab, mFOLFOX6 - Metastatic Colorectal Cancer (CRC) | Phase 3 | Unknown | Zhejiang Teruisi Pharmaceutical Inc. | 126 | 2022-08-01 | 2022-05-18 |
| Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression Bemarituzumab, mFOLFOX6, Placebo - Gastric Cancer, Gastroesophageal Junction Adenocarcinoma | Phase 3 | Completed | Amgen | 547 | 2022-03-07 | 2026-10-23 |
| Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418) mFOLFOX6, mFOLFOXIRI, FOLFIRI - Colorectal Cancer | Phase 3 | Recruiting | Dominik Paul Modest | 507 | 2021-12-06 | 2025-12-12 |
| Cetuximab Maintenance Treatment Versus Continuation After Induction Therapy in mCRC Cetuximab, mFOLFOX6, FOLFIRI - Colorectal Cancer | Phase 2 / Phase 3 | Unknown | Ruijin Hospital | 200 | 2021-11-01 | 2021-04-30 |
| The Value of Palliative Primary Tumor Resection in Metastatic Colon Cancer resection of primary tumor, XELOX, mFOLFOX6 - Metastatic Colon Cancer, Surgery | Phase 3 | Unknown | Fudan University | 627 | 2020-04-01 | 2020-06-04 |
| CIRCULATING TUMOR DNA BASED DECISION FOR ADJUVANT TREATMENT IN COLON CANCER STAGE II mFOLFOX6 - Patients With Resected Stage II Colon Cancer | Phase 3 | Recruiting | Centre Hospitalier Universitaire Dijon | 1980 | 2020-01-17 | 2026-07-10 |
| Varlitinib in Combination With mFOLFOX6 for Advanced or Metastatic Gastric Cancer (First Line) Varlitinib, mFOLFOX6, Placebo - Gastric Cancer | Phase 2 / Phase 3 | Completed | ASLAN Pharmaceuticals | 52 | 2017-08-31 | 2022-02-15 |
| IV Ascorbic Acid in Advanced Gastric Cancer ascorbic acid, mFOLFOX6 - Gastric Cancer | Phase 3 | Unknown | Sun Yat-sen University | 200 | 2017-03-12 | 2017-05-18 |
| Cetuximab Monotherapy Maintenance Treatment in mCRC Cetuximab, mFOLFOX6, FOLFIRI - Colorectal Cancer | Phase 2 / Phase 3 | Unknown | Ruijin Hospital | 500 | 2016-11-01 | 2016-11-30 |
| Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177) mFOLFOX6, FOLFIRI, Pembrolizumab - Colorectal Carcinoma | Phase 3 | Completed | Merck Sharp & Dohme LLC | 307 | 2015-11-30 | 2024-10-03 |
| Compare Efficacy and Safety of Raltitrexed-based and 5fu-based Neoadjuvant Chemotherapy for Colorectal Liver Metastasis Raltitrexed-based chemotherapy, 5-fluorouracil-based chemotherapy - Colorectal Cancer, Liver Metastasis | Phase 3 | Terminated | Zhejiang University | 360 | 2015-10-11 | 2020-07-14 |
| Synergistic Anti-tumor Effect of ChangTai Keli for Colon Cancer Patients mFOLFOX6, XELOX, Placebo ChangTai Keli - Colon Cancer | Phase 2 / Phase 3 | Unknown | Nanjing NingQi Medicine Science and Technology Co., Ltd. | 360 | 2015-06-01 | 2015-08-03 |
| Postoperative Hepatic Arterial Chemotherapy in High-risk Patients as Adjuvant Treatment After Resection of Colorectal Liver Metastases Oxaliplatin HAI, Oxaliplatin IV, mFOLFOX6 - Colorectal Cancer | Phase 2 / Phase 3 | Completed | Gustave Roussy, Cancer Campus, Grand Paris | 104 | 2015-05-26 | 2024-10-28 |
| A Study of Systemic Chemotherapy With/Without HAI in Patients With Initially Unresectable Colorectal Liver Metastasis mFOLFOX6, HAI - Metastatic Colorectal Cancer | Phase 3 | Unknown | Yuhong Li | 142 | 2014-03-01 | 2024-03-04 |
| A Study of Avastin (Bevacizumab) in Combination With mFOLFOX6 in Treatment-Naïve Patients With Metastatic Colorectal Cancer With or Without K-RAS Mutations, and Comparison to Cetuximab bevacizumab [Avastin], cetuximab, mFOLFOX6 - Colorectal Cancer | Phase 3 | Withdrawn | Hoffmann-La Roche | 2011-06-01 | 2016-11-02 |
Colorectal Neoplasms (12) · Stomach Neoplasms (3) · Colonic Neoplasms (2) · Neoplasm, Residual (1) · Parkinson Disease 4, Autosomal Dominant Lewy Body (1) · Rectal Neoplasms (1)
Ruijin Hospital (2) · Sun Yat-sen University (2) · ASLAN Pharmaceuticals (1) · Amgen (1) · Centre Hospitalier Universitaire Dijon (1) · Dominik Paul Modest (1) · Fudan University (1) · Genmab (1) · Gustave Roussy, Cancer Campus, Grand Paris (1) · Hoffmann-La Roche (1) · Jun Huang (1) · Merck Sharp & Dohme LLC (1) · Nanjing NingQi Medicine Science and Technology Co., Ltd. (1) · Sixth Affiliated Hospital, Sun Yat-sen University (1) · Yanhong Deng (1)
China (9) · France (3) · Australia (2) · Estonia (2) · Lithuania (2) · Malaysia (2) · Singapore (2) · South Korea (2) · Taiwan (2) · Thailand (2) · United States (2) · Argentina (1) · Belgium (1) · Brazil (1) · Bulgaria (1)
Ding Ke-Feng, PHD/MD (1) · Dominik Modest, Prof. Dr. (1) · Jun Huang, MD (1) · Jun Huang, PhD (1) · Jun Zhang, MD & Ph.D (1) · Rui-hua Xu, MD.,PhD. (1) · Xiaoning Wang, Professor (1) · Yanhong Deng, Ph.D. (1) · Yifeng Wang, MD (1) · Yu-hong Li, MD, Ph D (1)
PMID 30081865, PMID 33264544, PMID 33812497, PMID 35366831, PMID 35427471, PMID 36369901, PMID 38308771, PMID 40341124
2014 (1), 2015 (1), 2023 (1)